medigraphic.com

2019, Número 2

<< Anterior Siguiente >>

Rev Hematol Mex 2019; 20 (2)


Trombosis en pacientes con neoplasias hematológicas

Martínez-Murillo C, Flores-Ordoñez K, Ramos-Peñafiel CO, Castellanos-Sinco H, Barranco-Lampón G, Zazueta-Pozos JF, Collazo-Jaloma J

Idioma: Español
Referencias bibliográficas: 29
Paginas: 69-78
Archivo PDF: 627.32 Kb.


RESUMEN

La incidencia de trombosis en pacientes con linfoma no Hodgkin es igual o mayor que la reportada en los cánceres sólidos. Los pacientes con cáncer y trombosis tienen tasa de supervivencia más baja y mayor riesgo de mortalidad. Los factores que pueden predecir mayor riesgo de eventos trombóticos en los pacientes dependen de las características del paciente, el tipo de cáncer y el tipo de tratamiento. La información de la trombosis en pacientes con linfoma no Hodgkin es la misma que la información en el mundo y existe asociación entre la trombosis y el linfoma no Hodgkin, hemoglobina, leucocitos, plaquetas y DHL.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Trousseau ACJ, Bazire PV. Lectures on clinical medicine: delivered at the hotel-Dieu. Paris: New Sydenham Society; 1872.

  2. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122(10):1712-23.

  3. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M, Investigators R. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013;131(1):24-30.

  4. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167(14):1471-5.

  5. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013;49(6):1404-13.

  6. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6):715-22.

  7. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012;9(7):e1001275.

  8. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4(3):529-35.

  9. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119(3):648-55.

  10. Gade IL, Braekkan S, Naess IA, Hansen JB, Rosendaal F, Cannegieter S, et al. Epidemiology of venous thromboembolism in hematological cancers: the Scandinavian thrombosis and Cancer (STAC) cohort. Thromb Res 2017;158:157-60.

  11. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009;27(29):4848- 57.

  12. Khorana A, McCrae K. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 2014;133:S35-8.

  13. Franchini M. Thromboembolic risk in hematological malignancies. Clin Chem Lab Med 2015;53(8):1139-47.

  14. Ko R, Thornburg C. Venous thromboembolism children with cancer and blood disorders. Front Pediatr 2017;12:5-12.

  15. Cesarman-Maus G, Braggio E, Lome-Maldonado C, Morales-Leyte A, Fonseca R. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 2014;133(4):606-9.

  16. Wun T, White R. Venous thromboembolism in patients with acute leukemia, lymphoma and multiple myeloma. Thromb Res 2010;125:96-102.

  17. Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb Res 2012;129(3):360-6.

  18. Cohen A. Katholing A, Rietbrock S, Bamber L, Martínez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thromb Haemost 2017;117(1):57-65.

  19. Rupa-Matysek J, Brzezniakiewicz-Janus K, Gil L, Krasinski Z, Komarnicki M. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 2018;7(7):2868-2875.

  20. Khorana A, Kuderer N, Culakova E, Lyman G, Francis C. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood 2008;111(10)4902-4907.

  21. Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003;98(6):1239-42.

  22. Khorana A, Francias C. Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. Thromb Res 2018;164:S70-S76.

  23. Kenke N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev (2018) In press doi:10.1016/j.blre.2018.06.002

  24. Schmaier A, Ambesh P, Campial U. Venous Thromboembolism and Cancer. Curr Cardiol Rep 2018;20:89

  25. Wun T, White R. Venous thromboembolism in patients with acute leukemia, lymphoma and multiple myeloma. Thromb Res 2010;125:96-102.

  26. Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb Res 2012;129(3):360-6.

  27. Guzmán P, Vargas A. Thrombosis in leukemia: Incidence, Causes and Practical Management. Curr Oncol Rep 2015;17(4):444-52.

  28. Schmaier AA, Ambesh P, Umberto Campia U. Venous Thromboembolism and Cancer. Curr Cardiol Rep 2018;20:89.

  29. Mahajan A, Wun T, Chew H, White R. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res 2014;133:S23-8.




2020     |     www.medigraphic.com